Liquid chromatography-electrospray mass spectrometry determination of imatinib and its main metabolite, N-desmethyl-imatinib in human plasma

Journal of Liquid Chromatography and Related Technologies

Volumn 29, Issue 20, 2006, Pages 2957-2974

  Solassol, I ^a   Bressolle, F ^a,b   Philibert, L ^a,b   Charasson, V ^a,c   Astre, C ^a   Pinguet, F ^a  

^a CENTRE VAL D AURELLE   (France)

^b UNIV MONTPELLIER   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Human plasma; Imatinib; Liquid chromatography electrospray ionization mass spectrometry method; N desmethyl imatinib; Quantitation

Indexed keywords

BIOLOGICAL ORGANS; EXTRACTION; IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; NITROGEN COMPOUNDS;

HUMAN PLASMA; IMATINIB; LIQUID-CHROMATOGRAPHY/ELECTROSPRAY IONIZATION MASS SPECTROMETRY METHODS; N-DESMETHYL-IMATINIB; QUANTITATION;

BIODIVERSITY;

ACETONITRILE; FORMIC ACID; IMATINIB;

ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; STANDARD;

EID: 33750428597     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070600981058     Document Type: Article

References (18)

1. Novartis; Glivec. Summary of Product Characteristics 2001.
2. Cohen, M.H.; Williams, G.; Johnson, J.R.; Duan, J.; Gobburu, J.; Rahman, A.; Benson, K.; Leighton, J.; Kim, S.K.; Wood, R.; Rothmann, M.; Chen, G.; KM, U.; Staten, A.M.; Pazdur, R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 2002, 8, 935-942.
3. Gschind, H.P.; Pfaar, U.; Waldmeir, F.; Zollinger, M.; Sayer, C.; Zbinden, P.; Hayes, M.; Pkorny, R.; Seiberling, M.; Ben-Am, M.; Peng, B.; Gross, G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispo. 2005, 6, 1503-1512.
4. Peng, B.; Hayes, M.; Resta, D.; Racine-Poon, A.; Druker, B.J.; Talpaz, M.; Sawyers, C.L.; Rosamilia, M.; Ford, J.; Lloyd, P.; Capdeville, R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 2004, 22, 935-942.
5. Nimmanapalli, R.; Bhalla, K. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr. Opin. Oncol. 2002, 14, 616-620.
6. Schleyer, E.; Pursche, S.; Kohne, C.H.; Schuler, U.; Renner, U.; Gschaidmeier, H.; Freiberg-Richter, J.; Leopold, T.; Jenke, A.; Bonin, M.; Bergemann, T.; le Coutre, P.; Gruner, M.; Bornhauser, M.; Ottmann, O.G.; Ehninger, G. Liquid chromatograpihic method detection and quantification of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J. Chromatogr. B 2004, 799, 23-36.
7. Widmer, N.; Beguin, A.; Rochat, B.; Buclin, T.; Kovacsovics, T.; Duchosal, M.A.; Leyvraz, S.; Rosselet, A.; Biollaz, J.; Decosterd, L.A. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J. Chromatogr. B 2004, 803, 285-292.
8. Velpandian, T.; Mathur, R.; Agarwal, N.K.; Arora, B.; Kumar, L.S.; Gupta, S.K. Development and validation of a single liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J. Chromatogr. B 2004, 804, 431-434.
9. Bakhtiar, R.; Khemani, L.; Hayes, M.; Bedman, T.; Tse, F. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2002, 28, 1183-1194.
10. Bakhtiar, R.; Lohne, J.; Ramos, L.; Khemani, L.; Hayes, M.; Tse, F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (cgp 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2002, 768, 325-340.
11. Parise, R.A.; Ramanathan, R.K.; Hayes, M.J.; Egorin, M.J. Liquid chromatographic-mass spectrometric assay for quantification of imatinib and its metabolite (CGP 74588) in plasma. J. Chromatogr. B 2003, 791, 39-44.
12. Titier, K.; Picard, S.; Ducint, D.; Teilhet, E.; Moore, N.; Berthaud, P.; Mahon, F.; Molimard, M. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 2005, 27, 634-640.
13. Murall, M.; Rochat, B. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple quadrupole and linear ion trap mass spectrometers. J. Mass Spectrom. 2006, 41, 390-404.
14. US Food and Drug Administration, Guidance for industry, Bioanalytical Method Validation, http://www.fda.gov/cder/guidance/4252fnl.htm (accessed May 2004).
15. United States Pharmacopoeia XXXIII; The United States Pharmacopeia Convention: Rockville, Md, 2003; 2439.
16. Shah, V.P.; Midha, K.K.; Dighe, S.; McGilveray, I.J.; Skelly, J.P.; Yacobi, A.; Layloff, T.; Viswanathan, C.T.; Cook, C.E.; McDowall, R.D.; Pittman, K.A.; Spector, S. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 1992, 81, 309-312.
17. Bressolle, F.; Bromet-Petit, M.; Audran, M. Validation of liquid chromatographic and gas chromatographic methods. Applications in pharmacokinetics. J. Chromatogr. B 1996, 686, 3-10.
18. Matuszewski, B.K.; Constanzer, M.L.; Chavez-End, C.M. Matrrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per mililiter concentrations. Anal. Chem. 1998, 70, 882-889.